Tough break: Regado launches IPO at $4 per share
This article was originally published in Scrip
Executive Summary
Regado Biosciences just couldn't catch a break when it came to the 22 August initial public offering which will support the Basking Ridge, New Jersey-based company's massive late-stage study for its anticoagulant REG1.